![Page 1: Authors: de Wit R. et al, ASCO 2011 Abstract: 4509 Reviewed by: Dr. Lori Wood](https://reader036.vdocument.in/reader036/viewer/2022062520/56815a73550346895dc7d95b/html5/thumbnails/1.jpg)
www.OncologyEducation.ca
A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with
intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983).
Authors: de Wit R. et al, ASCO 2011Abstract: 4509Reviewed by: Dr. Lori WoodDate posted: June 2011
![Page 2: Authors: de Wit R. et al, ASCO 2011 Abstract: 4509 Reviewed by: Dr. Lori Wood](https://reader036.vdocument.in/reader036/viewer/2022062520/56815a73550346895dc7d95b/html5/thumbnails/2.jpg)
www.OncologyEducation.ca
Thank you for downloading this update. Please feel free to use it for educational purposes.
Please acknowledge OncologyEducation.ca and Dr. Lori Wood when using these slides.
![Page 3: Authors: de Wit R. et al, ASCO 2011 Abstract: 4509 Reviewed by: Dr. Lori Wood](https://reader036.vdocument.in/reader036/viewer/2022062520/56815a73550346895dc7d95b/html5/thumbnails/3.jpg)
www.OncologyEducation.ca
STUDY RATIONALE
• Since 1985, BEP chemotherapy is the gold standard treatment for all patients with metastatic GCTs– Cisplatin 20 mg/m2 d1-5– Etoposide 100 mg/m2 d1-5– Bleomycin 30 iu d2, d9, d16
• There are patients with intermediate and poor risk disease who still die of metastatic GCTs despite BEP
• There is a need to improve on standard BEP• Paclitaxel has shown activity in first-line and relapsed
GCTs• The idea was to bring Paclitaxel into the first-line setting
– 175 mg/m2 d1
![Page 4: Authors: de Wit R. et al, ASCO 2011 Abstract: 4509 Reviewed by: Dr. Lori Wood](https://reader036.vdocument.in/reader036/viewer/2022062520/56815a73550346895dc7d95b/html5/thumbnails/4.jpg)
www.OncologyEducation.ca
R
Treatment A: BEP + Paclitaxel x 4T-175 mg/m2 d1n=168GCSF
Treatment B:BEP x 4n=169
STUDY DESIGN
- IGCCC- Intermediate prognosis metastatic GCTs-Statistics: - 10% in 3-y PFS from 75% 85% - planned n=498 - closed with n=337 due to slow/poor accrual
![Page 5: Authors: de Wit R. et al, ASCO 2011 Abstract: 4509 Reviewed by: Dr. Lori Wood](https://reader036.vdocument.in/reader036/viewer/2022062520/56815a73550346895dc7d95b/html5/thumbnails/5.jpg)
www.OncologyEducation.ca
RESULTS
T-BEP BEP
n 168 169
Ineligible• good risk• poor risk
13
6
4
13
8
1
No Baseline Data 3 3
Eligible Patients 148 152
- Phase II accrual from November 1999 – March 2004. - Phase III accrual from March 2004 – August 2009 and then closed early. - Median follow-up = 5.3 years.
![Page 6: Authors: de Wit R. et al, ASCO 2011 Abstract: 4509 Reviewed by: Dr. Lori Wood](https://reader036.vdocument.in/reader036/viewer/2022062520/56815a73550346895dc7d95b/html5/thumbnails/6.jpg)
www.OncologyEducation.ca
RESULTS
T-BEP BEP HR p Value
N 168 169
Completed 4 Cycles 87.5% 92.3%
CR with Chemotherapy Only 65.1% 52.3%
CR with Chemotherapy/Surgery 70.4% 59.5% 0.055
3-y PFS (ITT) 79.4% 71.1%0.73
(0.47-1.13)0.153
3-y PFS (Eligible Patients) 82.7% 70.1%0.60
(0.37-0.97)0.03
3-y OS (ITT) 91.2% 89.8% 0.89 0.738
![Page 7: Authors: de Wit R. et al, ASCO 2011 Abstract: 4509 Reviewed by: Dr. Lori Wood](https://reader036.vdocument.in/reader036/viewer/2022062520/56815a73550346895dc7d95b/html5/thumbnails/7.jpg)
www.OncologyEducation.ca
STUDY COMMENTARY
• Primary endpoint of 3-y PFS was not met– But ineligible patients unbalanced between
the two arms
• Primary endpoint of eligible patients only – T-BEP better– 82.7% vs. 70.1% 3-y PFS
• Speculated that this was due to imbalance of ineligible patients between the two arms
• Two toxic deaths associated with T-BEP (1.3%)
![Page 8: Authors: de Wit R. et al, ASCO 2011 Abstract: 4509 Reviewed by: Dr. Lori Wood](https://reader036.vdocument.in/reader036/viewer/2022062520/56815a73550346895dc7d95b/html5/thumbnails/8.jpg)
www.OncologyEducation.ca
BOTTOM-LINE FOR CANADIAN MEDICAL ONCOLOGISTS
• Intriguing results but a positive trial only when data looked at eligible patients and not intention to treat analysis
• Given the great research question, it is hard to believe this study could not accrue and this fact really hurt this study
• I do not think we can incorporate these results into every day practice at this time